Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Probiotics in the Prevention and Treatment of Necrotizing Enterocolitis

  • Received : 2021.01.20
  • Accepted : 2021.03.24
  • Published : 2021.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Necrotizing enterocolitis (NEC) is a disease with high morbidity and mortality that occurs mainly in premature born infants. The pathophysiologic mechanisms indicate that gastrointestinal dysbiosis is a major risk factor. We searched for relevant articles published in PubMed and Google Scholar in the English language up to October 2020. Articles were extracted using subject headings and keywords of interest to the topic. Interesting references in included articles were also considered. Network meta-analysis suggests the preventive efficacy of Bifidobacterium and Lactobacillus spp., but even more for mixtures of Bifidobacterium, Streptococcus, and Bifidobacterium, and Streptococcus spp. However, studies comparing face-to-face different strains are lacking. Moreover, differences in inclusion criteria, dosage strains, and primary outcomes in most trials are major obstacles to providing evidence-based conclusions. Although adverse effects have not been reported in clinical trials, case series of adverse outcomes, mainly septicemia, have been published. Consequently, systematic administration of probiotic bacteria to prevent NEC is still debated in literature. The risk-benefit ratio depends on the incidence of NEC in a neonatal intensive care unit, and evidence has shown that preventive measures excluding probiotic administration can result in a decrease in NEC.

Keywords

References

  1. Bellodas Sanchez J, Kadrofske M. Necrotizing enterocolitis. Neurogastroenterol Motil 2019;31:e13569. https://doi.org/10.1111/nmo.13569
  2. Battersby C, Longford N, Mandalia S, Costeloe K, Modi N. Incidence and enteral feed antecedents of severe neonatal necrotising enterocolitis across neonatal networks in England, 2012-13: a whole-population surveillance study. Lancet Gastroenterol Hepatol 2017;2:43-51. https://doi.org/10.1016/S2468-1253(16)30117-0
  3. Boccia D, Stolfi I, Lana S, Moro ML. Nosocomial necrotising enterocolitis outbreaks: epidemiology and control measures. Eur J Pediatr 2001;160:385-91. https://doi.org/10.1007/s004310100749
  4. Samuels N, van de Graaf RA, de Jonge RCJ, Reiss IKM, Vermeulen MJ. Risk factors for necrotizing enterocolitis in neonates: a systematic review of prognostic studies. BMC Pediatr 2017;17:105. https://doi.org/10.1186/s12887-017-0847-3
  5. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr 2011;159:720-5. https://doi.org/10.1016/j.jpeds.2011.05.033
  6. Carrion V, Egan EA. Prevention of neonatal necrotizing enterocolitis. J Pediatr Gastroenterol Nutr 1990;11:317-23. https://doi.org/10.1097/00005176-199010000-00006
  7. Gray KD, Messina JA, Cortina C, Owens T, Fowler M, Foster M, et al. Probiotic use and safety in the neonatal intensive care unit: a matched cohort study. J Pediatr 2020;222:59-64.e1. https://doi.org/10.1016/j.jpeds.2020.03.051
  8. Chandran S, Anand AJ, Rajadurai VS, Seyed ES, Khoo PC, Chua MC. Evidence-based practices reduce necrotizing enterocolitis and improve nutrition outcomes in very low-birth-weight infants. JPEN J Parenter Enteral Nutr 2020. doi: 10.1002/jpen.2058. [Epub ahead of print].
  9. Sharif S, Meader N, Oddie SJ, Rojas-Reyes MX, McGuire W. Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants. Cochrane Database Syst Rev 2020;10:CD005496.
  10. Underwood MA, German JB, Lebrilla CB, Mills DA. Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut. Pediatr Res 2015;77:229-35. https://doi.org/10.1038/pr.2014.156
  11. Underwood MA. Probiotics and the prevention of necrotizing enterocolitis. J Pediatr Surg 2019;54:405-12. https://doi.org/10.1016/j.jpedsurg.2018.08.055
  12. Pammi M, Cope J, Tarr PI, Warner BB, Morrow AL, Mai V, et al. Intestinal dysbiosis in preterm infants preceding necrotizing enterocolitis: a systematic review and meta-analysis. Microbiome 2017;5:31. https://doi.org/10.1186/s40168-017-0248-8
  13. McMurtry VE, Gupta RW, Tran L, Blanchard EE 4th, Penn D, Taylor CM, et al. Bacterial diversity and Clostridia abundance decrease with increasing severity of necrotizing enterocolitis. Microbiome 2015;3:11. https://doi.org/10.1186/s40168-015-0075-8
  14. Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr 2010;51:2-7. https://doi.org/10.1097/MPG.0b013e3181d29767
  15. Wilson KH, Sheagren JN. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis 1983;147:733-6. https://doi.org/10.1093/infdis/147.4.733
  16. Meier PP, Johnson TJ, Patel AL, Rossman B. Evidence-based methods that promote human milk feeding of preterm infants: an expert review. Clin Perinatol 2017;44:1-22. https://doi.org/10.1016/j.clp.2016.11.005
  17. Yu Y, Lu J, Oliphant K, Gupta N, Claud K, Lu L. Maternal administration of probiotics promotes gut development in mouse offsprings. PLoS One 2020;15:e0237182. https://doi.org/10.1371/journal.pone.0237182
  18. Sodhi CP, Neal MD, Siggers R, Sho S, Ma C, Branca MF, et al. Intestinal epithelial Toll-like receptor 4 regulates goblet cell development and is required for necrotizing enterocolitis in mice. Gastroenterology 2012;143:708-18.e5. https://doi.org/10.1053/j.gastro.2012.05.053
  19. Hackam DJ, Sodhi CP, Good M. New insights into necrotizing enterocolitis: from laboratory observation to personalized prevention and treatment. J Pediatr Surg 2019;54:398-404. https://doi.org/10.1016/j.jpedsurg.2018.06.012
  20. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009;139:1619-25. https://doi.org/10.3945/jn.109.104638
  21. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr 2005;25:37-58. https://doi.org/10.1146/annurev.nutr.25.050304.092553
  22. Herrmann K, Carroll K. An exclusively human milk diet reduces necrotizing enterocolitis. Breastfeed Med 2014;9:184-90. https://doi.org/10.1089/bfm.2013.0121
  23. Dvorak B, Halpern MD, Holubec H, Williams CS, McWilliam DL, Dominguez JA, et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model. Am J Physiol Gastrointest Liver Physiol 2002;282:G156-64. https://doi.org/10.1152/ajpgi.00196.2001
  24. Good M, Sodhi CP, Egan CE, Afrazi A, Jia H, Yamaguchi Y, et al. Breast milk protects against the development of necrotizing enterocolitis through inhibition of Toll-like receptor 4 in the intestinal epithelium via activation of the epidermal growth factor receptor. Mucosal Immunol 2015;8:1166-79. https://doi.org/10.1038/mi.2015.30
  25. Good M, Siggers RH, Sodhi CP, Afrazi A, Alkhudari F, Egan CE, et al. Amniotic fluid inhibits Toll-like receptor 4 signaling in the fetal and neonatal intestinal epithelium. Proc Natl Acad Sci U S A 2012;109:11330-5. https://doi.org/10.1073/pnas.1200856109
  26. Gribar SC, Sodhi CP, Richardson WM, Anand RJ, Gittes GK, Branca MF, et al. Reciprocal expression and signaling of TLR4 and TLR9 in the pathogenesis and treatment of necrotizing enterocolitis. J Immunol 2009;182:636-46. https://doi.org/10.4049/jimmunol.182.1.636
  27. Lu P, Sodhi CP, Hackam DJ. Toll-like receptor regulation of intestinal development and inflammation in the pathogenesis of necrotizing enterocolitis. Pathophysiology 2014;21:81-93. https://doi.org/10.1016/j.pathophys.2013.11.007
  28. Mathipa MG, Thantsha MS. Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens. Gut Pathog 2017;9:28. https://doi.org/10.1186/s13099-017-0178-9
  29. Kumar A, Wu H, Collier-Hyams LS, Kwon YM, Hanson JM, Neish AS. The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol 2009;182:538-46. https://doi.org/10.4049/jimmunol.182.1.538
  30. Rivera-Chavez F, Lopez CA, Baumler AJ. Oxygen as a driver of gut dysbiosis. Free Radic Biol Med 2017;105:93-101. https://doi.org/10.1016/j.freeradbiomed.2016.09.022
  31. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol 2012;180:626-35. https://doi.org/10.1016/j.ajpath.2011.10.025
  32. Martinez FA, Balciunas EM, Converti A, Cotter PD, de Souza Oliveira RP. Bacteriocin production by Bifidobacterium spp. A review. Biotechnol Adv 2013;31:482-8. https://doi.org/10.1016/j.biotechadv.2013.01.010
  33. Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999;3:197-202. https://doi.org/10.1016/S1201-9712(99)90024-3
  34. Sawh SC, Deshpande S, Jansen S, Reynaert CJ, Jones PM. Prevention of necrotizing enterocolitis with probiotics: a systematic review and meta-analysis. PeerJ 2016;4:e2429. https://doi.org/10.7717/peerj.2429
  35. Patel RM, Denning PW. Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence? Clin Perinatol 2013;40:11-25. https://doi.org/10.1016/j.clp.2012.12.002
  36. Jacobs SE, Tobin JM, Opie GF, Donath S, Tabrizi SN, Pirotta M, et al. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 2013;132:1055-62. https://doi.org/10.1542/peds.2013-1339
  37. Costeloe K, Bowler U, Brocklehurst P, Hardy P, Heal P, Juszczak E, et al. A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial. Health Technol Assess 2016;20:1-94. https://doi.org/10.3310/hta20070
  38. Zozaya C, Garcia Gonzalez I, Avila-Alvarez A, Oikonomopoulou N, Sanchez Tamayo T, Salguero E, et al. Incidence, treatment, and outcome trends of necrotizing enterocolitis in preterm infants: a multicenter cohort study. Front Pediatr 2020;8:188. https://doi.org/10.3389/fped.2020.00188
  39. van den Akker CHP, van Goudoever JB, Shamir R, Domellof M, Embleton ND, Hojsak I, et al. Probiotics and preterm infants: a position paper by the European Society for Paediatric Gastroenterology Hepatology and Nutrition Committee on Nutrition and the European Society for Paediatric Gastroenterology Hepatology and Nutrition Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 2020;70:664-80. https://doi.org/10.1097/MPG.0000000000002655
  40. Chi C, Li C, Buys N, Wang W, Yin C, Sun J. Effects of probiotics in preterm infants: a network metaanalysis. Pediatrics 2021;147:e20200706. https://doi.org/10.1542/peds.2020-0706
  41. Morgan RL, Preidis GA, Kashyap PC, Weizman AV, Sadeghirad B; McMaster Probiotic, Prebiotic, and Synbiotic Work Group. Probiotics reduce mortality and morbidity in preterm, low-birth-weight infants: a systematic review and network meta-analysis of randomized trials. Gastroenterology 2020;159:467-80. https://doi.org/10.1053/j.gastro.2020.05.096
  42. Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus sepsis and probiotic therapy in newborns: two new cases and literature review. AJP Rep 2016;6:e25-9.
  43. Yelin I, Flett KB, Merakou C, Mehrotra P, Stam J, Snesrud E, et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med 2019;25:1728-32. https://doi.org/10.1038/s41591-019-0626-9
  44. Mack DR. D(-)-lactic acid-producing probiotics, D(-)-lactic acidosis and infants. Can J Gastroenterol 2004;18:671-5. https://doi.org/10.1155/2004/342583
  45. Papagaroufalis K, Fotiou A, Egli D, Tran LA, Steenhout P. A randomized double blind controlled safety trial evaluating d-lactic acid production in healthy infants fed a Lactobacillus reuteri-containing formula. Nutr Metab Insights 2014;7:19-27.
  46. Reddy VS, Patole SK, Rao S. Role of probiotics in short bowel syndrome in infants and children--a systematic review. Nutrients 2013;5:679-99. https://doi.org/10.3390/nu5030679
  47. Munakata S, Arakawa C, Kohira R, Fujita Y, Fuchigami T, Mugishima H. A case of D-lactic acid encephalopathy associated with use of probiotics. Brain Dev 2010;32:691-4. https://doi.org/10.1016/j.braindev.2009.09.024
  48. Codex Alimentarius Comission. Standard for infant formula and formulas for special medical purposes intended for infants [Internet]. Rome: Codex Alimentarius; 2016 [cited 2021 Feb 20]. Available from: http://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FStandards%252FCXS%2B72-1981%252FCXS_072e.pdf
  49. Lewis ZT, Shani G, Masarweh CF, Popovic M, Frese SA, Sela DA, et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 2016;79:445-52. https://doi.org/10.1038/pr.2015.244
  50. de Simone C. The unregulated probiotic market. Clin Gastroenterol Hepatol 2019;17:809-17. https://doi.org/10.1016/j.cgh.2018.01.018
  51. Akar M, Eras Z, Oncel MY, Arayici S, Guzoglu N, Canpolat FE, et al. Impact of oral probiotics on neurodevelopmental outcomes in preterm infants. J Matern Fetal Neonatal Med 2017;30:411-5. https://doi.org/10.1080/14767058.2016.1174683
  52. Garland SM, Tobin JM, Pirotta M, Tabrizi SN, Opie G, Donath S, et al. The ProPrems trial: investigating the effects of probiotics on late onset sepsis in very preterm infants. BMC Infect Dis 2011;11:210. https://doi.org/10.1186/1471-2334-11-210
  53. Guthmann F, Kluthe C, Buhrer C. Probiotics for prevention of necrotising enterocolitis: an updated meta-analysis. Klin Padiatr 2010;222:284-90. https://doi.org/10.1055/s-0030-1254113
  54. Adams M, Bassler D, Darlow BA, Lui K, Reichman B, Hakansson S, et al. Preventive strategies and factors associated with surgically treated necrotising enterocolitis in extremely preterm infants: an international unit survey linked with retrospective cohort data analysis. BMJ Open 2019;9:e031086. https://doi.org/10.1136/bmjopen-2019-031086
  55. Bertazzoni E, Donelli G, Midtvedt T, Nicoli J, Sanz Y. Probiotics and clinical effects: is the number what counts? J Chemother 2013;25:193-212. https://doi.org/10.1179/1973947813Y.0000000078
  56. Craighead AF, Caughey AB, Chaudhuri A, Yieh L, Hersh AR, Dukhovny D. Cost-effectiveness of probiotics for necrotizing enterocolitis prevention in very low birth weight infants. J Perinatol 2020;40:1652-61. https://doi.org/10.1038/s41372-020-00790-0
  57. Fleming P, Wilks M, Eaton S, Panton N, Hutchinson R, Akyempon A, et al. Bifidobacterium breve BBG-001 and intestinal barrier function in preterm babies: exploratory studies from the PiPS trial. Pediatr Res 2020. doi: 10.1038/s41390-020-01135-5. [Epub ahead of print].

Cited by

  1. Probiotics in Pediatrics. A Review and Practical Guide vol.13, pp.7, 2021, https://doi.org/10.3390/nu13072176